Nuclease News and Research

RSS

Sino Biological launches SuperNuclease® Pro with free trial program

Sino Biological, Inc., a global leader in recombinant technology, announced the launch of SuperNuclease® Pro (Cat#: SSNP02).

From Sino Biological Inc. 31 Jul 2026

Excess EXO1 protein may drive cancer DNA damage and treatment response

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells.

21 May 2026

New CRISPR system selectively destroys cancer cells

Among the challenges in treating disease, including cancer, is wiping out malignancies, infection, contaminants or other pathologies, without destroying healthy tissue.

6 May 2026

Non-clinical safety assessment crucial for CRISPR-based gene therapies

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling precise correction, disruption, and regulation of disease-associated genes.

10 Apr 2026

Broken String Biosciences rebrands to reflect strategic evolution as demand grows for unbiased genome-wide off-target analysis

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning.

From Broken String Biosciences 31 Mar 2026

CRISPR-Cas3: A safer gene-editing tool shows promise for transthyretin amyloidosis treatment

Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism. Transthyretin amyloidosis (ATTR) is a progressive disorder involving amyloid deposits of misfolded transthyretin (TTR) proteins.

14 Jan 2026

New method can help better assess precision genome editing technology

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR gene editing technology focus on identifying small off-target sites that pose a safety risk, which is also technically challenging.

2 Jan 2026

New insights into alcohol-related DNA damage and cancer risk

Alcohol consumption leads to the formation of a toxic compound called acetaldehyde, which damages DNA.

15 Dec 2025

Researchers discover the enzyme responsible for chromothripsis in cancer

University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which a single chromosome is shattered into pieces and rearranged in a scrambled order, allowing cancer cells to rapidly evolve and become resistant to treatment.

11 Dec 2025

BindCraft reimagines protein binder discovery through structural prediction

Physical interactions between proteins influence anything from cell signaling and growth to immune responses, so the ability to control these interactions is of great interest to biologists.

29 Aug 2025

Mitochondrial DNA editing offers new hope for neurodegenerative disease treatment

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs).

12 May 2025

New gene editing tool enables precise control of mitochondrial mutation load

Mitochondrial diseases affect approximately 1 in 5,000 people worldwide, causing debilitating symptoms ranging from muscle weakness to stroke-like episodes.

3 May 2025

New enzyme family enables targeted cuts in single-stranded DNA

An INRS team discovers a new family of enzymes capable of inducing targeted cuts in single-stranded DNA .

16 Apr 2025

Fruit flies steal bacterial defense to survive parasitic wasps

In the continual arms race between parasites and their hosts, innovation was thought to be the key to a successful attack or defense that one-ups the competition.

24 Dec 2024

First U.S. trial uses non-viral CRISPR to correct sickle cell mutation

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease.

26 Nov 2024

Persistent activation of DNA damage response in the liver after MASLD reversal

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced form, metabolic dysfunction-associated steatohepatitis, have emerged as the most prevalent liver diseases worldwide.

25 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024